



Express Mail No.: EV452773488US

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application Srivastava et al.  
of:

Serial No.: 09/668,724

Filed: September 22, 2000

For: ALPHA (2) MACROGLOBULIN  
RECEPTOR AS A HEAT SHOCK PROTEIN  
RECEPTOR AND USES THEREOF

Confirmation No.: 1804

Art Unit: 1642

Examiner: Christopher H. Yaen

Attorney Docket No: 8449-128-999

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

**Mail Stop Amendment**

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

In accordance with the continuing duty of disclosure imposed by 37 C.F.R. §1.56 to inform the U.S. Patent and Trademark Office of all references coming to the attention of each individual associated with the filing and prosecution of the subject application which are or may be material to the patentability of any claim of the application, Attorneys for Applicants respectfully direct the Examiner's attention to the references C02-C07 listed on the attached revised form PTO 1449 entitled "List of References Cited by Applicant." Copies of references C02-C07 are enclosed.

Identification of the listed references is not to be construed as an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application.

Applicants request that the Examiner review all the references identified on the attached revised PTO Form 1449, and that they be made of record in the file history of the above-identified application.

11/16/2004 LWONDIM1 00000001 503013 09668724


01 FC:1806 180.00 DA

1551585-1

This Supplemental Information Disclosure Statement is being filed before a mailing of a final Office Action. As such, according to 37 CFR § 1.97(c), Applicants believe that a fee of \$180.00 is due in accordance with 37 CFR § 1.17(p). Please charge the required fee to Jones Day Deposit Account No. 503013. A duplicate copy of this sheet is enclosed for accounting purposes.

Date: November 8, 2004

Respectfully submitted,

 32,605  
Adriane M. Antler (Reg. No.)

**JONES DAY**  
222 East 41<sup>st</sup> Street  
New York, New York 10017-6702  
(212) 326-3939

Enclosures

**LIST OF REFERENCES CITED BY APPLICANT**

(Use several sheets if necessary)

ATTY DOCKET NO.

8449-128-999

APPLICATION NO.

09/668,724

APPLICANT

Srivastava et al.

FILING DATE

September 22, 2000

GROUP

1642

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

**FOREIGN PATENT DOCUMENTS**

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
					YES NO

**OTHER REFERENCES** (Including Author, Title, Date, Pertinent Pages, Etc.)

C02	Binder and Srivastava, 2004, Essential role of CD91 in re-presentation of gp96-chaperoned peptides. Proc. Natl. Acad. Sci. U.S.A. 101:6128-6133.	
C03	Binder <i>et al.</i> , 2002, Naturally formed artificially reconstituted non-covalent alpha 2-macroglobulin-peptide complexes elicit CD91-dependent cellular immunity. Cancer Immunity 2:16-24.	
C04	Basu <i>et al.</i> , 2001, CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity 14:303-313.	
C05	Herz and Strickland, 2001, LRP: a multifunctional scavenger and signaling receptor. J. Clin. Invest. 108:779-784.	
C06	Goto and Tanzi, 2002, The role of the low-density lipoprotein receptor-related protein (LRP1) in Alzheimer's Abeta generation. J. Mol. Neurosci. 19:37-41.	
C07	The Merck Manual of Diagnosis and Therapy, 1999, Beers and Berkow eds., Merck Research Laboratories, Whitehouse Station N.J., pp. 1871 and 1872.	

**EXAMINER****DATE CONSIDERED**

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.